SCHEMBL10154348

SCHEMBL10154348

CNCC1CCCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
GRIN2B Q13224 8/20 0.52
CYP2C19 P33261 1/20 0.51
CYP2D6 P10635 4/20 0.51
CYP2C9 P11712 4/20 0.51
HTT P42858 1/20 0.49
JAK2 O60674 2/20 0.48
JAK1 P23458 2/20 0.48
TYK2 P29597 2/20 0.48
JAK3 P52333 2/20 0.48
CYP3A4 P08684 3/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
BCL9 O00512 1/20 0.47
CTNNB1 P35222 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22869197 0.86 SMN1; SMN2 (0.56) LCKSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL10153811 0.85 GRIN2B (0.69) SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19
SCHEMBL3272711 0.85 SMN1; SMN2 (0.58) LCKSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL3277927 0.85 SMN1; SMN2 (0.58) LCKSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL1320424 0.85 SMN1; SMN2 (0.58) LCKSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL1843641 0.84 SMN1; SMN2 (0.56) LCKSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL2499417 0.84 SMN1; SMN2 (0.56) LCKSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL8696423 0.84 SMN1; SMN2 (0.56) LCKSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL736958 0.84 SMN1; SMN2 (0.57) LCKSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL7572788 0.84 SMN1; SMN2 (0.56) LCKSMN1; SMN2NPC1RAB9AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
WO-2010092962-A1 HETERO RING DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA LCK 71/4885SMN1; SMN2 4237/4885NPC1 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.